Raquibul Hannan, M.D., Ph.D. Titles and Appointments Chief of Genitourinary Radiation Oncology Service Professor School Medical School Department Radiation Oncology | Immunology | Urology Graduate Programs Cancer Biology You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Raquibul Hannan, M.D., Ph.D., is a Professor of Radiation Oncology and Chief of Genitourinary Radiation Oncology Service at UT Southwestern Medical Center. Dr. Hannan earned his medical degree from State University of New York (SUNY) at Brooklyn’s Downstate College of Medicine and his Ph.D. from the SUNY Downstate School of Graduate Studies. He completed his radiation oncology residency training at Albert Einstein College of Medicine and Montefiore Medical Center. Dr. Hannan leads the Hannan Lab at UT Southwestern, which aims to understand and exploit the immunogenic properties of tumor irradiation in integrating it with immunotherapy to improve cancer patient outcomes. His lab is currently involved in performing translational studies on a number of stereotactic ablative radiotherapy (SAbR) and i-SAbR (immunotherapy + SAbR) clinical trials. Dr. Hannan has led and completed multiple investigator-initiated clinical trials investigating the application of SAbR for prostate and kidney cancer. He is the national Chair/PI of a phase three randomized trial SOAR (EA-8211) that is investigating SAbR in oligometastatic renal cell carcinoma patients. In the clinic, he is investigating the application of adaptive SAbR or PULSAR (Personalized Ultra-fractionated Stereotactic Ablative Radiation) for the treatment of locally advanced and metastatic kidney cancer. As a leading researcher on immunologic effects of radiation and immunotherapy, Dr. Hannan holds two international patents and has presented his findings at numerous symposiums and conferences across the world. He is a member of several professional societies, including the American Society of Radiation Oncology (ASTRO), the American Board of Radiology (ABR), and the American Society of Clinical Oncology (ASCO). Education Graduate School SUNY Downstate Medical Center (2002) Medical School SUNY Downstate Medical Center (2006) Internship SUNY Downstate Medical Center (2007), Internal Medicine Residency Montefiore Med. Ctr. & Albert Einstein College of Med. (2011), Radiation Oncology Research Interest Identifying novel indications for SAbR and PULSAR for genitourinary malignancies Improving cancer patient treatment outcomes through the design of combined immunotherapy and SAbR (i-SAbR) clinical trials Innate and adaptive immune responses generated by tumor irradiation with stereotactic ablative radiotherapy (SAbR) Investigating the application and integration of SAbR and adaptive SAbR (PULSAR) for all stages of kidney cancer Publications Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice Guide Barbour AB, Upadhyay R, Anderson AC, Kutuk T, Kumar R, Wang SJ, Psutka SP, Fekrmandi F, Skalina KA, Bruynzeel AM, Correa RJ, Dal Pra A, Biancia CD, Hannan R, Louie A, Singh AK, Swaminath A, Tang C, Teh BS, Zaorsky NG, Lo SS, Siva S Practical Radiation Oncology 2025 Jan 15 74-85 Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer Ali M, Kwon YS, Koo K, Bruynzeel A, Pryor D, Schep DG, Huo M, Stein M, Swaminath A, Hannan R, Siva S BJU international 2025 Jan 135 110-116 Stereotactic ablative radiotherapy for primary kidney cancer – An international patterns of practice survey Taplin K, Hannan R, Lo SS, Morgan SC, Ali M, Sigurdson S, Guckenberger M, Swaminath A Clinical and Translational Radiation Oncology 2025 Jan 50 Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney Tan VS, Correa RJ, Warner A, Ali M, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, Suk Kwon Y, Morgan SC, Cury FL, Teh BS, Mahadevan A, Kaplan ID, Chu W, Hannan R, Staehler M, Zaorsky NG, Louie AV, Siva S European Urology Oncology 2024 Dec 7 1527-1534 Mapping cellular interactions from spatially resolved transcriptomics data Zhu J, Wang Y, Chang WY, Malewska A, Napolitano F, Gahan JC, Unni N, Zhao M, Yuan R, Wu F, Yue L, Guo L, Zhao Z, Chen DZ, Hannan R, Zhang S, Xiao G, Mu P, Hanker AB, Strand D, Arteaga CL, Desai N, Wang X, Xie Y, Wang T Nature methods 2024 Oct 21 1830-1842 Adrenal Insufficiency following Stereotactic Ablative Radiotherapy (SAbR) of Adrenal Gland Metastases Hamidi O, Miljanic M, Tumyan G, Christie A, Mirfakhraee S, Ali S, Dohopolski M, Gottumukkala S, Brugarolas J, Timmerman R, Hannan R Cancers 2024 Sep 16 Corrigendum to “Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial” [Eur. Eurol. 84(2) (2023) 156–163, (S0302283823027884), (10.1016/j.eururo.2023.04.024)] Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin M, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Neil Reaume M, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA European urology 2024 Sep 86 289-290 Performance deterioration of deep learning models after clinical deployment: a case study with auto-segmentation for definitive prostate cancer radiotherapy Wang B, Dohopolski M, Bai T, Wu J, Hannan R, Desai N, Garant A, Yang D, Nguyen D, Lin MH, Timmerman R, Wang X, Jiang SB Machine Learning: Science and Technology 2024 Jun 5 Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CA, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, Duncan CE, Rodgers JP, Feng F, Sandler HM JAMA Oncology 2024 May 10 584-591 Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology Marvaso G, Jereczek-Fossa BA, Zaffaroni M, Vincini MG, Corrao G, Andratschke N, Balagamwala EH, Bedke J, Blanck O, Capitanio U, Correa RJ, De Meerleer G, Franzese C, Gaeta A, Gandini S, Garibaldi C, Gerszten PC, Gillessen S, Grubb WR, Guckenberger M, Hannan R, Jhaveri PM, Josipovic M, Kerkmeijer LG, Lehrer EJ, Lindskog M, Louie AV, Nguyen QN, Ost P, Palma DA, Procopio G, Rossi M, Staehler M, Tree AC, Tsang YM, Van As N, Zaorsky NG, Zilli T, Pasquier D, Siva S The Lancet Oncology 2024 May 25 e193-e204 Results 1-10 of 92 1 2 3 4 5 Next Last Honors & Awards U.S. PatentPancreatic Cancer-Associated Antigen, Antibody thereto, and Diagnostic and Treatment Methods Development of a PaCa-Ag1-Specific Enzyme-Linked Immuno-Assay (2006) International PatentPancreatic Cancer-Associated Antigen, Antibody thereto, and Diagnostic and Treatment Methods (2005) Professional Associations/Affiliations American College of Radiology (ACR) (2008) American Society for Radiology Oncology (ASTRO) (2008) American Society of Clinical Oncology (ASCO) (2010) Society for Immunotherapy Cancer (SITC) (2014)
